6 November 2017 - A much-lauded savings measure for the Pharmaceutical Benefits Scheme came up $840 million short last year when the returns to government and taxpayers were 26% lower than forecast.

While price disclosure is still delivering savings, the shock ­result is the biggest variation since the measure was introduced a decade ago and raises questions about whether market conditions have changed or the modelling is wrong.

Federal Health Minister Greg Hunt will not update savings forecasts until the next budget in six months and also has other changes to price disclosure before parliament.

Read The Australian article